New results from a survey of 550 Wegovy users found patients reported a major drop in "food noise," or intrusive thoughts ...

"That's an easy move to make out of the gate, but it's also unusual at Novo, and it's piqued investor interest," said ...

Investing.com - 诺和诺德公司表示，其实验性Wegovy口服药在后期临床试验中显示出显著的减重效果，与之前注射版本的结果相当。这些发现于周三发表在《新英格兰医学杂志》上。

据媒体报道，诺和诺德已提交新药上市申请，美国食品药品监督管理局（FDA）将于年底前审查。 诺和诺德的口服版减重药物Wegovy在减重试验中接近注射版本的效果。 在一项新发表的研究中，诺和诺德(NVO.N)的口服司美格鲁肽25毫克（WEGOVY®片剂* ...

Among 77,310 adults without diabetes who began taking semaglutide after it was approved for weight loss, 40,262 (52%) were no ...

The Danish drugmaker said a clinical trial showed participants who got a pill form of Wegovy lost an average of 16.6 percent ...

Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.

德国拜罗伊特大学的 Othmar Moser 教授领导了这项研究，他表示：“基于肠促胰素的疗法，如奥земпіс、Wegovy 和 Mounjaro，被广泛用于体重管理，但它们对味觉的影响尚不清楚。”Moser 教授认为：“如果味觉的变化与更好的食欲控制和体重减轻有关，这可能有助于临床医生更好地选择疗法，提供更有针对性的饮食建议，并改善患者的长期治疗效果。” ...

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

Hi, this is Naomi. I’m off to Vienna for a diabetes conference, and I’ve come across a lesser-known GLP-1 side effect. More ...

一项研究显示，更高剂量的减肥药物司美格鲁肽（semaglutide，以品牌名Wegovy更为人所知）可能帮助人们减掉高达25%的体重，且不会带来严重的副作用。该结论基于两项近期发布的临床试验结果。

Danish multinational pharmaceutical company Novo Nordisk’s obesity drug Wegovy (semaglutide 2.4 mg) cut risk of heart attack, ...